JP2019532928A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532928A5
JP2019532928A5 JP2019515241A JP2019515241A JP2019532928A5 JP 2019532928 A5 JP2019532928 A5 JP 2019532928A5 JP 2019515241 A JP2019515241 A JP 2019515241A JP 2019515241 A JP2019515241 A JP 2019515241A JP 2019532928 A5 JP2019532928 A5 JP 2019532928A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
heteroaryl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532928A (ja
JP6997178B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/051692 external-priority patent/WO2018053215A1/en
Publication of JP2019532928A publication Critical patent/JP2019532928A/ja
Publication of JP2019532928A5 publication Critical patent/JP2019532928A5/ja
Priority to JP2021203942A priority Critical patent/JP7281527B2/ja
Application granted granted Critical
Publication of JP6997178B2 publication Critical patent/JP6997178B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515241A 2016-09-16 2017-09-15 ベータラクタマーゼ阻害剤化合物 Active JP6997178B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021203942A JP7281527B2 (ja) 2016-09-16 2021-12-16 ベータラクタマーゼ阻害剤化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395464P 2016-09-16 2016-09-16
US62/395,464 2016-09-16
US201762456423P 2017-02-08 2017-02-08
US62/456,423 2017-02-08
PCT/US2017/051692 WO2018053215A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021203942A Division JP7281527B2 (ja) 2016-09-16 2021-12-16 ベータラクタマーゼ阻害剤化合物

Publications (3)

Publication Number Publication Date
JP2019532928A JP2019532928A (ja) 2019-11-14
JP2019532928A5 true JP2019532928A5 (enExample) 2020-10-01
JP6997178B2 JP6997178B2 (ja) 2022-02-03

Family

ID=60083416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019515241A Active JP6997178B2 (ja) 2016-09-16 2017-09-15 ベータラクタマーゼ阻害剤化合物
JP2021203942A Active JP7281527B2 (ja) 2016-09-16 2021-12-16 ベータラクタマーゼ阻害剤化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021203942A Active JP7281527B2 (ja) 2016-09-16 2021-12-16 ベータラクタマーゼ阻害剤化合物

Country Status (24)

Country Link
US (1) US10800778B2 (enExample)
EP (1) EP3512851B1 (enExample)
JP (2) JP6997178B2 (enExample)
KR (2) KR102667828B1 (enExample)
CN (2) CN109715630B (enExample)
AU (1) AU2017325863B2 (enExample)
CA (1) CA3036557A1 (enExample)
CY (1) CY1125826T1 (enExample)
DK (1) DK3512851T3 (enExample)
ES (1) ES2927986T3 (enExample)
HR (1) HRP20221217T1 (enExample)
HU (1) HUE060282T2 (enExample)
IL (2) IL289686B2 (enExample)
LT (1) LT3512851T (enExample)
MA (1) MA46242A (enExample)
MX (2) MX385507B (enExample)
PH (1) PH12019500558B1 (enExample)
PL (1) PL3512851T3 (enExample)
PT (1) PT3512851T (enExample)
SG (1) SG11201901658PA (enExample)
SI (1) SI3512851T1 (enExample)
SM (1) SMT202200397T1 (enExample)
TW (1) TWI773687B (enExample)
WO (1) WO2018053215A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196909A (en) 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
CA3036557A1 (en) * 2016-09-16 2018-03-22 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
PL3630111T3 (pl) 2017-05-08 2022-05-23 Entasis Therapeutics, Inc. Związki i sposoby leczenia zakażeń bakteryjnych
AU2019256351B2 (en) 2018-04-20 2024-02-29 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102790878B1 (ko) 2018-08-09 2025-04-02 앤타바이오 에스에이에스 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN112209928B (zh) * 2019-07-10 2023-02-17 华东理工大学 共价键标记丝氨酸类beta-内酰胺酶的试剂及制备和应用
CN110898999A (zh) * 2019-11-26 2020-03-24 中国矿业大学 一种煤焦油基煤泥浮选药剂及其制备方法
US12552815B2 (en) 2020-05-05 2026-02-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN111790439B (zh) * 2020-07-29 2022-12-27 成都能特科技发展有限公司 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用
WO2022047603A1 (en) 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
CA3212788A1 (en) * 2021-04-05 2022-10-13 Qpex Biopharma, Inc. Ceftibuten dosing regimens
EP4146651B1 (en) 2021-05-07 2026-03-04 Ningxia Academy of Agriculture and Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) * 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023206580A1 (en) 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms
US20230398101A1 (en) * 2022-06-09 2023-12-14 Fleurir Abx Llc Co-agents as Therapy Against Anaerobic Pathogens
CN118271319B (zh) * 2022-12-30 2025-02-28 成都四面体药物研究有限公司 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
CN118772145B (zh) * 2023-04-04 2025-10-10 上海医药工业研究院有限公司 一种二氮杂双环辛烯化合物的制备方法
CN116693531A (zh) * 2023-06-09 2023-09-05 河南师范大学 一种桥联多环内酰胺类化合物的合成方法
WO2025106662A1 (en) * 2023-11-15 2025-05-22 Entasis Therapeutics, Inc. Preparation of boronic acid intermediates useful for the preparation of compounds for treating bacterial infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
NZ274915A (en) 1993-12-29 1997-11-24 Pfizer N-(hetero)aryl methyl diazabicycloalkane derivatives
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
MY162532A (en) * 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP3260551A1 (en) 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
SG184958A1 (en) * 2010-04-20 2012-11-29 Taisho Pharmaceutical Co Ltd Novel hydroxamic acid derivative
MX362683B (es) 2011-07-26 2019-01-31 Wockhardt Ltd Composiciones farmacéuticas que comprenden antibiótico de beta-lactama, sulbactama e inhibidor de beta-lactamasa.
MX338610B (es) 2011-07-26 2016-04-25 Wockhardt Ltd Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
KR101512738B1 (ko) * 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
KR101618424B1 (ko) 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
MX2014011825A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
KR20140144254A (ko) 2012-03-30 2014-12-18 큐비스트 파마슈티컬즈 인코포레이티드 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 β-락타마제 억제제
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
CA2881169C (en) 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
CA2889793C (en) 2012-09-03 2017-09-26 Wockhardt Limited Antibacterial compositions
CN104994860A (zh) 2013-02-06 2015-10-21 阿斯利康(瑞典)有限公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
BR112017010132B1 (pt) 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes
WO2016156348A1 (en) * 2015-03-31 2016-10-06 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
CA3036557A1 (en) * 2016-09-16 2018-03-22 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
KR20230007830A (ko) * 2021-07-06 2023-01-13 현대자동차주식회사 고강성 저선팽창 열가소성 수지 조성물 및 이를 포함하는 성형체

Similar Documents

Publication Publication Date Title
HRP20221217T1 (hr) Spojevi inhibitori beta-laktamaze
JP2016506960A5 (enExample)
JP2018507890A5 (enExample)
JP2021534124A5 (enExample)
JP2015535847A5 (enExample)
JP2010524932A5 (enExample)
JP2010530372A5 (enExample)
JP2020507589A5 (enExample)
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
JP2018504437A5 (enExample)
RU2015100901A (ru) Производные эфира гетероарилкарбоновой кислоты
JP2011526283A5 (enExample)
RU2017138972A (ru) Ингибиторы репликации вируса иммунодефицита человека
JP2013508297A5 (enExample)
JP2016503052A5 (enExample)
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
HRP20090077B1 (hr) Modulatori farmakokinetičkih svojstava terapeutika
JP2014500870A5 (enExample)
JP2017509689A5 (enExample)
EA201391158A1 (ru) Диаминиевые соли фенотиазина и их применение
JP2014511891A5 (enExample)
JP2013544812A5 (enExample)
JP2016503797A5 (enExample)
JP2017533263A5 (enExample)
TNSN06377A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists